# Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)

> **NCT01844518** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 219 (actual)

## Conditions studied

- Active Polyarticular Juvenile Idiopathic Arthritis

## Interventions

- **BIOLOGICAL:** Abatacept

## Key facts

- **NCT ID:** NCT01844518
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-30
- **Primary completion:** 2015-03-12
- **Final completion:** 2023-02-01
- **Target enrollment:** 219 (ACTUAL)
- **Last updated:** 2023-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01844518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01844518, "Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01844518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*